Patents Examined by Craig Ricci
  • Compounds and compositions for the treatment of parasitic disease
    Patent number: 9963454
    Abstract: The invention provides a class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent malaria.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: May 8, 2018
    Assignee: Novartis AG
    Inventors: Arnab K. Chatterjee, Kelli L. Kuhen, Advait S. Nagle, David C. Tully, Tao Wu
  • Aminobenzamide derivatives as useful agents for controlling animal parasites
    Patent number: 9944604
    Abstract: The invention relates to a composition comprising at least one aminobenzamide compound or a salt thereof for controlling animal parasites, veterinary pharmaceutical compositions comprising at least one aminobenzamide of formula (I) for preventing infection with diseases transmitted through parasites, its use for the preparation of a veterinary pharmaceutical for controlling animal parasites, and a method for preventing infection with diseases transmitted through parasites.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: April 17, 2018
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Ulrich Görgens, Akihiko Yanagi, Kazue Yanagi, Keisuke Yanagi, Kasumi Yanagi, Katsuaki Wada, Tetsuya Murata, Yukiyoshi Watanabe, Jun Mihara, Koichi Araki
  • Compositions and methods for modulating c-Rel-dependent cytokine production
    Patent number: 9910031
    Abstract: The present invention is directed to compositions and methods for modulating c-Rel-dependent cytokine production without materially altering the level of expression of NF?B and/or the amount of I?B. The present invention is also directed to screening for modulators of c-Rel activity as determined by assaying for altered subcellular localization of c-Rel but where the level of expression of NF?B and/or the amount of I?B is materially unaltered.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: March 6, 2018
    Assignee: Madrigal Pharmaceuticals, Inc.
    Inventors: Rongzhen Lu, James Barsoum, Yumiko Wada
  • Conjugates comprising cell-binding agents and cytotoxic agents
    Patent number: 9901647
    Abstract: The invention provides linker compounds and cytotoxic compounds that are useful for forming a CBA-drug conjugates; and conjugates so formed. Such conjugates and/or cytotoxic compounds may be effective for treating a range of diseases, such as cancer, with a relatively high activity at a relatively low, non-toxic dose.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: February 27, 2018
    Assignee: IMMUNOGEN, INC.
    Inventor: Wayne C. Widdison
  • Compositions and methods of treating retinal disease
    Patent number: 9896419
    Abstract: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: February 20, 2018
    Assignee: ALDEYRA THERAPEUTICS, INC.
    Inventors: Thomas A. Jordan, John E. Dowling, John Clifford Chabala
  • Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same
    Patent number: 9895378
    Abstract: The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid and a therapeutic agent (1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea), or pharmaceutically acceptable salts thereof, and a polymer. Other aspects include methods of making and using such nanoparticles.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: February 20, 2018
    Assignee: Pfizer Inc.
    Inventors: Shubha Bagrodia, Jennifer Lafontaine, Zach Lovatt, Eyoung Shin, Young Ho Song, Greg Troiano, Hong Wang
  • Compounds and compositions for the treatment of cancer
    Patent number: 9890127
    Abstract: Disclosed are compounds, such as pyridazinones, that can be, inter alia, used for treating cancer.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: February 13, 2018
    Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Timothy A. Lewis, Benito Munoz, Lucian De Waal, Heidi Greulich, Matthew Meyerson, Lara Nicole Gechijian
  • Salt and crystal forms of PLK-4 inhibitor
    Patent number: 9884855
    Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: February 6, 2018
    Assignee: University Health Network
    Inventors: Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
  • Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
    Patent number: 9877952
    Abstract: The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: January 30, 2018
    Assignee: PTC Therapeutics, Inc.
    Inventors: Samit Hirawat, Langdon Miller
  • Composition and methods for the production of S-adenosylmethionine within the body
    Patent number: 9877939
    Abstract: Described herein is a method for increasing levels of S-adenosylmethionine within the human body without administering S-adenosylmethionine directly. The method of the invention may be achieved by administering one or more of L-methionine, methylcobalamin, 5-Methyl tetrahydrofolate, betaine, and malic acid, together. with at least one compound selected from the group consisting of folic acid, vitamin B12, magnesium, calcium, and other cofactors.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: January 30, 2018
    Assignee: Fast Balance, LLC
    Inventor: Brian D. Halevie-Goldman
  • Ladostigil therapy for immunomodulation
    Patent number: 9867798
    Abstract: Methods for treating individuals suffering from inflammation, specifically systemic inflammation including septic shock and inflammatory conditions affecting the gastrointestinal, myocardial and endocrine systems with ladostigil.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: January 16, 2018
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventor: Marta Weinstock-Rosin
  • Regulation of osteopontin
    Patent number: 9867794
    Abstract: The present invention provides methods for the regulation of osteopontin activity in a subject as well as for treating or preventing conditions associated with an increased activity of osteopontin activity in a subject.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: January 16, 2018
    Assignee: Pathologica LLC
    Inventors: Kenneth G. Hadlock, Hope Lancero, Stephanie Yu, Hien Kim Do
  • Tricyclic sulphonamide compounds and methods of making and using same
    Patent number: 9868717
    Abstract: The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: January 16, 2018
    Assignee: Zafgen, Inc.
    Inventors: Thomas D. Pallin, Susan M. Cramp, Hazel J. Dyke, Robert Zahler
  • Indole amide compound as inhibitor of necrosis
    Patent number: 9868731
    Abstract: The present invention relates to an indole amide compound represented by formula (1), a pharmaceutically acceptable salt or isomer thereof, a composition for prevention or treatment of necrosis and necrosis-associated diseases, and a method for preparing the composition, the composition comprising the indole compound or the pharmaceutically acceptable salt or isomer thereof as an active ingredient.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: January 16, 2018
    Assignee: LG CHEM, LTD.
    Inventors: Heui Sul Park, Sun Young Koo, Hyoung Jin Kim, Sung Bae Lee, Hyo Shin Kwak, Seung Yup Paek, Soon Ha Kim
  • Substituted bicyclic heteroaryl compounds as RXR agonists
    Patent number: 9862713
    Abstract: The present invention relates to certain substituted bicyclic compounds that are agonists of RXR and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: January 9, 2018
    Assignee: CONNEXIOS LIFE SCIENCES PVT. LTD.
    Inventors: Madhavan Gurram Ranga, Jagannath Rao, Chandra Sekhar Gudla
  • Buprenorphine-wafer for drug substitution therapy
    Patent number: 9861628
    Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: January 9, 2018
    Assignee: RHODES PHARMACEUTICALS L.P.
    Inventors: Alexander Oksche, William Heath, Timothy Holden, Derek A. Prater, Richard S. Sackler, Malcolm Walden
  • Methods of treating hepatic encephalopathy
    Patent number: 9855254
    Abstract: The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: January 2, 2018
    Assignee: Salix Pharmaceuticals, Ltd.
    Inventors: William Forbes, Kunal Merchant, Enoch Bortey, Audrey Shaw
  • Gene signature to predict homologous recombination (HR) deficient cancer
    Patent number: 9850542
    Abstract: Methods for identifying and treating cancers that are homologous recombination (HR)-repair defective. In some aspects, HR defective cancers are treated with a PARP inhibitor therapy. Methods for sensitizing cancers to a PARP inhibitor therapy are also provided.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: December 26, 2017
    Assignee: Board of Regents, The University of Texas System
    Inventors: Chun-Jen Lin, Guang Peng, Shiaw-Yih Lin, Gordon B. Mills
  • Compositions and methods for inhibiting cytochrome P450
    Patent number: 9849107
    Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: December 26, 2017
    Assignee: SEQUOIA PHARMACEUTICALS, INC.
    Inventors: Michael Eissenstat, Dehui Duan
  • Sigma ligands for use in the prevention and/or treatment of post-operative pain
    Patent number: 9844516
    Abstract: The invention refers to the use of a sigma ligand, particularly a sigma ligand of formulae (I), (II) or (III) to prevent and/or treat acute and chronic pain developed as a consequence of surgery, especially superficial and/or deep pain secondary to surgical tissue injury, and peripheral neuropathic pain, neuralgia, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuritis or neuropathy secondary to surgical procedure.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: December 19, 2017
    Assignee: Laboratorios De Dr. Esteve
    Inventors: José Miguel Vela Hernández, Daniel Zamanillo-Castanedo, Margarita Puig Riera de Conias